Table 4 Time to treatment, time to resolution, and duration of attack for icatibant-treated breakthrough attacks by type of LTP
Type of LTP | ||||||
|---|---|---|---|---|---|---|
LTP | Androgensa | Tranexamic acid | C1-INH | Otherb | No LTP | |
No. patients | 93 | 56 | 24 | 5 | 9 | 179 |
No. attacksc | 391 | 226 | 92 | 36 | 37 | 781 |
Time to treatment | ||||||
Median (IQR), h | 1.5 (0.5–4.0) | 1.3 (0.5–4.0) | 2.0 (0.5–5.9) | 1.5 (0.1–2.1) | 0.8 (0.5–2.0) | 1.0 (0.3–4.0) |
P valued | 0.090 | 0.095 | 0.745 | 0.681 | 0.029 | |
Time to resolution | ||||||
Median (IQR), h | 4.5 (2.0–12.0) | 5.0 (2.0–11.5) | 7.0 (2.0–20.5) | 3.0 (2.4–4.0) | 4.0 (2.0–24.5) | 6.0 (2.0–14.6) |
P value | 0.869 | 0.642 | 0.317 | 0.103 | 0.565 | |
Duration of attack | ||||||
Median (IQR), h | 8.0 (4.0–17.0) | 8.0 (3.5–17.0) | 11.6 (6.0–25.3) | 4.0 (3.1–5.8) | 7.0 (3.0–25.0) | 9.0 (3.8–20.0) |
P value | 0.543 | 0.984 | 0.016 | 0.041 | 0.741 | |